The Latest
-
This week in charts
This week in charts: Brain drugs are back on venture capitalists’ minds
Five neurology-focused startups have together raised around $450 million in the last few weeks. Elsewhere, investors had a muted response to the latest cell therapy research.
-
Big-name investors pour $100M into DNA therapeutics developer Seawolf
The startup, which also just disclosed an up to $1.2 billion partnership with Sanofi, is backed by Versant, MPM BioImpact, Eli Lilly and Novartis’ venture arm.
-
Deep Dive // Emerging biotech
Biotech startups are built on venture capital. Track funding rounds here.
At least four neuroscience-focused biotechs have raised venture fundings since late October, matching the total number of rounds raised by brain drug developers over the previous six months, according to BioPharma Dive data.
Updated Nov. 12, 2026 -
IPO window
Windward prices $175M IPO to advance China-licensed lung drugs
The Swiss biotech, which pocketed another $50 million through a concurrent private share sale to Sanofi, is developing a potential competitor to the blockbuster asthma treatment Tezspire.
-
News roundup
Novo submits sickle cell drug; Flagship, Gates Foundation deepen ties
Novo views the medicine, acquired in a billion-dollar deal, as a future blockbuster. Meanwhile, a pair of startups forged an RNA editing pact and Astellas lined up two new trials in pancreatic cancer.
-
China competition
BIO unveils plan for US to remain biotech’s ‘global leader’
A seven-part proposal from the prominent lobbyist lays out a series of initiatives to accelerate drug development in the U.S. and counter China’s fast rise.
-
Obesity drugs
Blackstone bets $1.5B on Pfizer’s obesity drug
The deal will support a sprawling Phase 3 program for a monthly GLP-1 shot Pfizer acquired by winning a bidding war for the drug’s previous owner, Metsera.
-
Bristol Myers research chief to depart in ‘evolution’ of company’s structure
Robert Plenge is leaving as part of a shift that will see the company merge together its R&D department in a bid to speed development and capitalize on new technologies.
-
Drug price hikes in Germany could push US costs higher, study says
The report comes amid escalating tensions between the U.S. and Germany over drug prices, with several large pharmaceutical companies responding by scaling back investments in the country.
-
Trump administration
The FDA has over 1k open jobs — and the staffing shortage is hitting pharma
The agency is still recovering from a mass staff exodus last year that left it shorthanded. Here’s what it means for the industry.
-
News roundup
AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning
The deal gives AstraZeneca a simpler way to make conjugate vaccines. Elsewhere, a psychedelic depression drug was submitted to the FDA and an autoimmune disease-focused biotech’s shares collapsed.
-
Gene editing
Beam’s base editing therapy for sickle cell hits goal in pivotal trial
The result represents a scientific milestone and positions Beam to submit a first-of-its-kind FDA application as soon as the end of the year.
-
PepGen soars on promising early data for muscular dystrophy drug
While from a small study, the findings suggest PepGen’s therapy compares favorably to other RNA-based medicines in testing at Novartis and Dyne Therapeutics.
-
Trump administration
Ramaswamy’s biotech baggage haunted his political run
A pivotal Alzheimer’s trial tied to Vivek Ramaswamy’s political rise is a tale of failed endpoints.
-
National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
Brain drug revivalLondon biotech Oyster harvests $60M for tau-targeting brain drugs
Oyster says a tweak it's made to traditional protein degrading technology can help break down tau, which has long been a focus of Alzheimer’s drug research.
-
Deep Dive // IPO window
Biotech IPOs are the industry’s lifeblood. Track how they’re performing.
Rezera and Windward Bio are set to go public Wednesday and Thursday, respectively, in a pair of offerings that could each pull in more than $200 million.
Updated Nov. 11, 2026 -
Bayer wins FDA nod for a new kind of blood thinner
Sunharbo’s U.S. approval is the first for a “Factor XIa” inhibitor, an anticipated class of medicines seen as a possible step forward in stroke prevention.
-
Novartis reveals cancer cases possibly linked to gene therapy Zolgensma
The FDA is now investigating the risk of malignancy associated with Zolgensma and is “evaluating whether regulatory action is appropriate.”
Updated Nov. 9, 2026 -
Argenx to buy peptide platform in potentially billion-dollar deal
For $550 million up front, Argenx will take control of Unnatural Products’ “macrocyclic peptide” technology and direct it to develop oral, durable medicines for serious immune-mediated diseases.
-
This week in charts
This week in charts: 3 drug launches Wall Street is watching
The latest installment in BioPharma Dive’s visualization-focused series features a look at investors’ response to a trio of medicines highlighted in quarterly earnings this week.
-
Vir hepatitis D drug succeeds in first pivotal study
A program that’s survived Vir’s pivot away from infectious disease research hit all of its study objectives and appeared more potent than a rival drug also in late-stage development.
-
Deep Dive
Biotech M&A is accelerating. Track the deals that are happening here.
Lilly and Johnson & Johnson on Monday added to a run of private company acquisitions that has accounted for the majority of the sector’s dealmaking activity in 2026.
Updated 9 hours ago -
News roundup
Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down
The deal is part of a course change for Hims, which had previously sold knockoff GLP-1 drugs. Elsewhere, a medicine Servier recently acquired failed a key trial and Ultragenyx announced staff cuts.
-
At ASH, drugmakers to showcase early data for three-pronged cancer therapies
J&J and AbbVie are among the companies advancing “trispecific” antibodies that could become another step forward in treatment for multiple myeloma.
-
Trump administration
Biopharma likely to climb higher after ‘blue wave,’ analysts say
Historical data suggests the sector outperforms after midterm elections. And Democrats, newly in control of Congress, have “bigger fish to fry” than drug pricing, analysts said.